Context Therapeutics Inc’s filing revealed that its Chief Executive Officer Lehr Martin A. acquired Company’s shares for reported $70080.0 on Jun 09 ’25. In the deal valued at $0.70 per share,100,000 shares were bought. As a result of this transaction, Lehr Martin A. now holds 920,190 shares worth roughly $1.08 million.
Then, Levit Alex C. bought 20,000 shares, generating $11,520 in total proceeds. Upon buying the shares at $0.58, the Chief Legal Officer, Corp. Sec now owns 29,000 shares.
Before that, Minai-Azary Jennifer Lynn bought 40,010 shares. Context Therapeutics Inc shares valued at $25,486 were divested by the Chief Financial Officer at a price of $0.64 per share. As a result of the transaction, Minai-Azary Jennifer Lynn now holds 80,010 shares, worth roughly $93611.7.
Guggenheim initiated its Context Therapeutics Inc [CNTX] rating to a Buy in a research note published on September 18, 2025; the price target was $5. A number of analysts have revised their coverage, including William Blair’s analysts, who began to cover the stock in late April with a ‘”an Outperform”‘ rating. JMP Securities began covering CNTX with “Mkt outperform” recommendation on January 08, 2025. D. Boral Capital started covering the stock on November 25, 2024. It rated CNTX as “a Buy”.
Price Performance Review of CNTX
On Tuesday, Context Therapeutics Inc [NASDAQ:CNTX] saw its stock fall -4.88% to $1.17. Over the last five days, the stock has lost -7.87%. Context Therapeutics Inc shares have fallen nearly -50.21% since the year began. Nevertheless, the stocks have risen 11.43% over the past one year. While a 52-week high of $2.40 was reached on 10/10/25, a 52-week low of $0.49 was recorded on 05/30/25.
Levels Of Support And Resistance For CNTX Stock
The 24-hour chart illustrates a support level at 1.1347, which if violated will result in even more drops to 1.0993. On the upside, there is a resistance level at 1.2307. A further resistance level may holdings at 1.2913.
How much short interest is there in Context Therapeutics Inc?
A steep rise in short interest was recorded in Context Therapeutics Inc stocks on 2025-10-15, dropping by 41168.0 shares to a total of 0.47 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 0.51 million shares. There was a decline of -8.84%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on May 16, 2024 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $4.50 price target.
